Last reviewed · How we verify

Pramlintide + Insulin

Montefiore Medical Center · FDA-approved active Small molecule

Pramlintide + Insulin is a Amylin analog + Insulin combination Small molecule drug developed by Montefiore Medical Center. It is currently FDA-approved for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin). Also known as: Pramlintide Acetate.

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes. Used for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

At a glance

Generic namePramlintide + Insulin
Also known asPramlintide Acetate
SponsorMontefiore Medical Center
Drug classAmylin analog + Insulin combination
TargetAmylin receptor (pramlintide component); Insulin receptor (insulin component)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Pramlintide is an amylin analog that acts as a neuroendocrine regulator to delay gastric emptying, suppress postprandial glucagon secretion, and promote satiety. When combined with insulin, it provides complementary glucose-lowering effects: insulin drives glucose uptake and storage, while pramlintide reduces the rate of nutrient absorption and hepatic glucose production after meals. This combination addresses multiple pathophysiologic defects in diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pramlintide + Insulin

What is Pramlintide + Insulin?

Pramlintide + Insulin is a Amylin analog + Insulin combination drug developed by Montefiore Medical Center, indicated for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

How does Pramlintide + Insulin work?

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.

What is Pramlintide + Insulin used for?

Pramlintide + Insulin is indicated for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

Who makes Pramlintide + Insulin?

Pramlintide + Insulin is developed and marketed by Montefiore Medical Center (see full Montefiore Medical Center pipeline at /company/montefiore-medical-center).

Is Pramlintide + Insulin also known as anything else?

Pramlintide + Insulin is also known as Pramlintide Acetate.

What drug class is Pramlintide + Insulin in?

Pramlintide + Insulin belongs to the Amylin analog + Insulin combination class. See all Amylin analog + Insulin combination drugs at /class/amylin-analog-insulin-combination.

What development phase is Pramlintide + Insulin in?

Pramlintide + Insulin is FDA-approved (marketed).

What are the side effects of Pramlintide + Insulin?

Common side effects of Pramlintide + Insulin include Hypoglycemia, Nausea, Vomiting, Anorexia, Injection site reactions.

What does Pramlintide + Insulin target?

Pramlintide + Insulin targets Amylin receptor (pramlintide component); Insulin receptor (insulin component) and is a Amylin analog + Insulin combination.

Related